Hepion Pharmaceuticals Announces Publication of Food Effect Study with Rencofilstat
20 oct. 2022 16h30 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals to Participate in the ThinkEquity Conference
19 oct. 2022 08h00 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
26 sept. 2022 17h00 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Upcoming Presentation at Joint Meeting of ISBRA and ESBRA to Highlight Potential of Hepion Pharmaceutical’s Rencofilstat to Treat Alcohol-Related Liver Disease
14 sept. 2022 08h00 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals Announces Initiation of Dosing in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial
12 sept. 2022 08h00 HE
|
Hepion Pharmaceuticals, Inc.
- Hepion Collaborates with HepQuant and Summit Clinical Research to Evaluate Rencofilstat’s Impact on Hepatic Function and Numerous NASH Functional Biomarkers - - F3 NASH Subjects will be Evaluated...
Hepion Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
08 sept. 2022 08h00 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals Announces Initiation of Phase 2b ‘ASCEND-NASH’ Trial
31 août 2022 08h00 HE
|
Hepion Pharmaceuticals, Inc.
- Hepion Screens First Subject in Biopsy-Confirmed F2/F3 NASH Study - - Subjects will be Evaluated on Three Doses of Rencofilstat for a One-year Period - EDISON, N.J., Aug. 31, 2022 (GLOBE...
Hepion Pharmaceuticals Announces Further Adjournment of Annual Meeting of Stockholders
22 juil. 2022 16h15 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., July 22, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven...
Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati
28 juin 2022 08h30 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven...
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders
24 juin 2022 16h15 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., June 24, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven...